News

Intermarket transactions (IMTs) are a core part of the EMVS but present their own unique challenges.

The Latvian Medicines Verification Organization (LZVO) is launching The Newsletter No. 6, where you can find the most important information about events in the world of medicines verification in the second quarter of 2023.

The European Medicines Verification Organisation (EMVO) has launched a newsletter, which informs about the statement from EMVO’s new President, the roles and responsibilities of the National Medicines Verification Organisations (NMVO) Observers, the experience from the Hungarian Medicines Verification Organisation in ending the stabilisation period, the Belgium's experience with the Nordic recommendations on the recalls of batches and withdrawal of products, as well as on the status of alerts in the European Medicines Verification System (EMVS).

European Medicines Verification Organisation (EMVO) would like to highlight once again the consequences following Product Withdrawal and Batch recall and remind you that these are irreversible actions.

On May 12, at the European Medicines Verification Organisation’s (EMVO) General Assembly meeting, the NMVO Observers within EMVO’s Board for 2023 from the National Medicines Verification Organizations (NMVOs) were approved. As one of the observers representing the group of small-scale countries, will be the Latvian Medicines Verification Organisation (LZVO) and its Chairwoman of the Board Inese Erdmane.

The Latvian Medicines Verification Organisation (LZVO) in the fifth issue of the Newsletter (April 2023) looks back at the celebration of the fourth anniversary of the medicine verification system and looks at the current affairs of the first quarter of 2023.